Partnering At Every Stage: Choosing Andelyn To Provide ‘Capable Capacity' For Cell And Gene Therapy Manufacturing

Many challenges can stall an advanced therapy’s development, with most tied to inadequate preclinical planning and partner vetting. Drug developers can prevent issues before they arise and avoid the rework and delays that can torpedo timelines and derail development. This can be done by anticipating and addressing issues early with a capable, full-service manufacturing partner that will work to optimize variables such as plasmid and vector design, yield, analytical development, and production pathway early, and by prioritizing downstream considerations such as final regulatory package.

Finding this capable contract development and manufacturing organization (CDMO) partner with the requisite expertise, materials, external supply chain, and capacity to handle today’s increasingly complex landscape can be a challenge. Andelyn Biosciences is that capable partner with the expertise to overcome these challenges, providing the full range of services from pre-clinical through clinical and commercial.

Andelyn Biosciences is a biopharmaceutical CDMO with a 20+ year track record in gene therapy research, development, and manufacturing. Andelyn has extensive expertise in viral vector process and analytical development, small- to large-scale adherent- and suspension-based GMP drug substance manufacturing up to 2,000L, and finished drug product manufacturing services. We have also invested years of research in our plasmid production capabilities, as well as in the analytical capabilities and next-generation technologies necessary for innovating in the advanced cell and gene therapy space.